ILUMYA DOSING & ADMINISTRATION

ENHANCE ADHERENCE WITH QUARTERLY IN-OFFICE ADMINISTRATION OF ILUMYA®1

Which patients could benefit most from an in-office injection 4 times a year?

Hospital Building IconHospital Building Icon

HEALTHCARE PROFESSIONAL ADMINISTRATION

Prescribing ILUMYA® (tildrakizumab-asmn) helps you stay in control of dosing with in-office administration and oversight of patients who struggle with treatment compliance and comorbidities.1,2

Storage Calendar Icon

ILUMYA® IS THE ONLY SINGLE-INJECTION IL-23 INHIBITOR WITH QUARTERLY DOSING2-4

ILUMYA 52-Week Dosing Graph
Dosing Body Icon

1 DOSE = ONE 100 mg/mL INJECTION

The 100 mg dose of ILUMYA® is recommended for all patients, regardless of weight.2

Dosing frequency of treatments for moderate-to-severe plaque psoriasis*

ILUMYA_1_YRILUMYA®(tildrakizumab)14INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance doseIL-23 INHIBITOR
  • SKYRIZI_1_YRSkyrizi®(risankizumab)28INJECTIONS3 Following 2 starter doses at Weeks 0 and 4TWO 75 mg injections per Q12W maintenance doseIL-23 INHIBITOR
  • TREMFYA_1_YRTremfya®(guselkumab)21INJECTIONS4Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q8W maintenance doseIL-23 INHIBITOR
  • PDE4 INHIBITOROtezla®(apremilast)2189TABLETS5Following initial titration ofone 10 mg dose on Day 1,two 10 mg doses on Day 2,two doses (one 10 mg andone 20 mg) on Day 3,two 20 mg doses on Day 4,and two doses (one 20 mgand one 30 mg) on Day 5ONE 30 mg tabletper BIDmaintenance dose
  • ENBREL_1_YREnbrel®(etanercept)168INJECTIONS6 Following twice weekly dosing for the first 3 months†ONE 50 mg injection per QW maintenance doseTNF INHIBITOR
  • HUMIRA_1_YRHumira®(adalimumab)79INJECTIONS7Following one 80 mg starter doseONE 40 mg injection per QOW maintenance doseTNF INHIBITOR
ILUMYA_1_YRIL-23 INHIBITORILUMYA®(tildrakizumab)6INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance dose
  • SKYRIZI_1_YRSkyrizi®(risankizumab)12INJECTIONS3 Following 2 starter doses at Weeks 0 and 4TWO 75 mg injections per Q12W maintenance doseIL-23 INHIBITOR
  • TREMFYA_1_YRIL-23 INHIBITORTremfya®(guselkumab)8INJECTIONS4Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q8W maintenance dose
  • OTEZLA_1_YRPDE4 INHIBITOROtezla®(apremilast)729TABLETS5Following initial titration of one 10 mg dose on Day 1, two 10 mg doses on Day 2, two doses (one 10 mg and one 20 mg) on Day 3, two 20 mg doses on Day 4, and two doses (one 20 mg and one 30 mg) on Day 5ONE 30 mg tablet per BID maintenance dose
  • ENBREL_1_YRTNF INHIBITOREnbrel®(etanercept)64INJECTIONS6 Following twice weekly dosing for the first 3 months†ONE 50 mg injection per QW maintenance dose
  • HUMIRA_1_YRTNF INHIBITORHumira®(adalimumab)27INJECTIONS7Following one 80 mg starter doseONE 40 mg injection per QOW maintenance dose

This graphic is not intended to compare the efficacy or safety of the treatments shown here. Additional considerations, aside from the dosing profile, should be taken into account before making a treatment decision. For complete product information, refer to each product’s Prescribing Information.

*Indications and dosage information accessed October 2020. For complete product information, including current indications and dosing, refer to each product’s Prescribing Information.

†Reflects adult dosing. Alternative starting doses include 25 mg or 50 mg weekly.

Indicated trademarks are registered trademarks of their respective owners.

Skyrizi® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tremfya® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Otezla® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Humira® is indicated for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Administering ILUMYA® (tildrakizumab-asmn)2

Administration Step 1: Waiting Clock Icon

1

Let the ILUMYA® carton sit at room temperature for at least 30 minutes before injecting.

Administration Step 2: Injection Site Body Icon

2

Choose an injection site with clear skin and easy access (such as the abdomen, thigh, or upper arm).

Administration Step 3: Tildrakizumab Syringe Icon

3

Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe.

Administration Step 4: Hazardous Waste Bucket Icon

4

Discard the syringe after use.

Watch a healthcare professional (Dr. George Han) follow step-by-step instructions to properly inject ILUMYA® into a real patient.

Storage Calendar Icon

ROOM TEMPERATURE STABILITY CAN ALLOW FOR STORAGE FLEXIBILITY2

ILUMYA® should be refrigerated. 30 minutes before injecting, let ILUMYA® sit at room temperature. Once stored at room temperature, do not place back in the refrigerator. However, 30-day room temperature stability means ILUMYA® can be administered later if your patient misses their appointment.

CONSISTENT, LONG-TERM CLEARANCE

See lasting results with ILUMYA® through Year 38

Explore Efficacy

DURABLE SAFETY PROFILE

From Clinical Trial 1 and reSURFACE 1 and 29

SEE 3-YEAR SAFETY

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

Infections

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.

 

References: 1. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. 2. ILUMYA® [package insert]. Princeton, NJ: Sun Pharmaceutical Industries, Inc. 3. Skyrizi® (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc. 4. Tremfya® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 5. Otezla® (apremilast) [package insert]. Summit, NJ: Celgene Corporation. 6. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation. 7. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 8. Data on File. Sun Pharmaceutical Industries, Inc. 9. Thaçi D, Iversen L, Pau-Charles I, et al. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Paper presented at: 27th Congress of the European Academy of Dermatology and Venereology (EADV); September 12-16, 2018; Paris, France.